Abstract:Background: The role of locoregional radiotherapy in patients with primary metastatic nasopharyngeal carcinoma (mNPC) is unclear.Methods: In our open-label, phase 3, multi-centre randomized controlled trial, patients with primary mNPC, staged at IVc at the diagnosis of NPC were enrolled.Key inclusion criteria were CR or PR evaluated by imaging study after three cycles of chemotherapy according to the RECST v1.1; a KPS of at least 70.Eligible patients were randomly assigned in a 1:1 ratio to receive either chemotherapy plus radiotherapy or chemotherapy alone.Chemotherapy regimens were fluorouracil at 5 g/m 2 over 120 h and cisplatin at 100 mg/m 2 on day 1 once every 3 weeks for a maximum of six cycles.The primary endpoint was OS.We did efficacy analyses in ITT population.Safety analyses were done in patients receiving allocated treatment.This study is registered with ClinicalTrials.gov,number NCT02111460, and is ongoing.Results: Between April 2014 and August 2018, 126 eligible patients were randomly assigned to receive chemotherapy plus radiotherapy (n ¼ 63), or chemotherapy alone (n ¼ 63).In August 2018, the randomization was temporarily suspended due to an imbalance in deaths between the two groups and the ad hoc IDMC and the ethics committee of SYSUCC both recommended that the trial be permanently closed to new patient enrollment after IDMC confirmed the previously identified imbalance with this additional follow-up data in February 2019.The median follow-up time for OS was 25.2 months.The median OS was 40.2 months (95%CI 25.7-54.7) in the chemotherapy plus radiotherapy group and 24.5 months (95%CI 15.3-33.7) in the chemotherapy alone (HR 0.45 95% CI 0.25-0.80;P ¼ 0.007).No significant differences between the two treatment groups were observed in terms of hematological toxicity and gastrointestinal reaction.The frequency of grade 2-3 skin reaction and grade 3-4 mucositis in chemotherapy plus radiotherapy was significantly higher than those in chemotherapy alone groups (P < 0.05).Conclusions: Chemotherapy plus radiotherapy significantly improved overall survival in primary metastatic nasopharyngeal carcinoma with acceptable toxicity and tolerability.

Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas

Survival benefit of radiotherapy for metastatic nasopharyngeal carcinoma: a retrospective analysis based on SEER database

Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma

Retrospective Analysis of 234 Nasopharyngeal Carcinoma Patients with Distant Metastasis at Initial Diagnosis: Therapeutic Approaches and Prognostic Factors

Locoregional Radiotherapy in Patients with Distant Metastases of Nasopharyngeal Carcinoma at Diagnosis

Local Radiotherapy Versus Nonradiotherapy to Distant Lesions for Metastatic Nasopharyngeal Carcinoma: Retrospective Cohort Study

Impact of Radiotherapy Combined with Chemotherapy on Long-Term Outcomes of Patients with Recurrent Nasopharyngeal Carcinoma

Intensive Local Radiotherapy Is Associated With Better Local Control And Prolonged Survival In Bone-Metastatic Nasopharyngeal Carcinoma Patients

Curative Effects and Late Phase Reactions of Nasopharyngeal Carcinoma Treated with Radiotherapy in 246 Cases

Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study

Survival Benefit with Palliative Local Radiotherapy in Metastatic Nasopharyngeal Carcinoma

Long-term Results of Nasopharyngeal Carcinoma Treated with Radiotherapy:1706 Cases Report

Prognostic Analysis of 152 Patients with Distant Metastasis after Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

Chemotherapy plus radiotherapy makes curability a possibility in nasopharyngeal carcinoma patients with distant metastasis at diagnosis

Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients with Newly Diagnosed Metastatic Nasopharyngeal Cancer

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients.

Intensity-modulated Radiotherapy Prolongs the Survival of Patients with Nasopharyngeal Carcinoma Compared with Conventional Two-Dimensional Radiotherapy: A 10-Year Experience with a Large Cohort and Long Follow-Up

Multimodality Treatment May Improve The Survival Rate Of Patients With Metastatic Nasopharyngeal Carcinoma With Good Performance Status

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Systemic Chemotherapy and Sequential Locoregional Radiotherapy in Initially Metastatic Nasopharyngeal Carcinoma: Retrospective Analysis with 821 Cases